EUCTR2017-003369-85-NL进行中（未招募）1 期
A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. - MODIFY
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed and dated ICF prior to any study-mandated procedure.
- •2. Male or female subjects; 18-years old and above.
- •3. FD diagnosis confirmed with local genetic test results
- •(i.e., presence of at least 1 mutation in GLA, the gene coding for a-galactosidase A)
- •4. Fabry-associated neuropathic pain, as defined by the subject, in the last 3 months prior to screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 89
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Pregnant, planning to be become pregnant up to 30 days after study
- •treatment discontinuation or lactating subject;
- •2. Severe renal insufficiency defined as an estimated glomerular
- •filtration rate (eGFR) per the Chronic Kidney Disease Epidemiology
- •Collaboration creatinine equation < 30 mL/min/1.73 m2 at screening;
- •3. Subject on regular dialysis for the treatment of chronic kidney
- •4. Subject has undergone, or is on a waiting list for, or is scheduled to
- •undergo kidney or other organ transplantation;
- •5. Known and documented transient ischemic attack, stroke, unstable
- •angina or myocardial infarction within 6 months prior to screening;
- •6. Clinically significant unstable cardiac disease in the opinion of the
- •investigator (e.g., uncontrolled symptomatic arrhythmia, New York
- •Heart Association class III or IV congestive heart failure);
- •7. Any other subject at high risk for developing clinical signs of organ
- •involvement within the time period of the study, as per investigator
- •8. Subject planned for imminent initiation of treatment with ERT.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of apraglutide in short bowel syndrome and intestinal failureEUCTR2020-001202-32-NOVectivBio AG164
进行中（未招募）
不适用
A multicenter, double-blind, randomized, placebo-controlled, two-arm parallel-group study of BGG492 as monotherapy in individuals with refractory partial seizures undergoing inpatient evaluation for epilepsy surgeryMedDRA version: 9.1Level: LLTClassification code 10061334Term: Partial seizuresEpilepsyEUCTR2008-005065-64-DEovartis Pharma Services AG
进行中（未招募）
1 期
A research study to study the effects of a new oral drug called lucerastat in adults with Fabry diseaseFabry diseaseMedDRA version: 20.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-003369-85-GBIdorsia Pharmaceuticals Ltd99
进行中（未招募）
不适用
A multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and tolerability of AVE5530 when added to ongoing stable statin therapy at high doses in patients with severe primary hypercholesterolemiaPrimary HypercholesterolemiaMedDRA version: 11.0Level: LLTClassification code 10060375Term: <Manually entered code. Term in E.1.1>EUCTR2008-002849-23-BESanofi-Aventis Recherche & Développement668
进行中（未招募）
不适用
A multicenter, double-blind, randomized, placebo-controlled, 4 parallel groups, dose-ranging trial evaluating the efficacy and safety of ucb 34714 used as adjunctive treatment at doses of 50, 150 and 400 mg/day in b.i.d. administration (oral capsules of 25 or 50 mg) for a maximum of 13 weeks in subjects from 16 to 65 years with refractory epilepsy suffering from partial onset seizures whether or not secondarily generalized - ucb 34714 dose-rangingEUCTR2004-001856-35-FICB S.A. Pharma Sector245